Immutep are global leaders in the understanding and development of therapeutics that modulate Lymphocyte Activation Gene-3 or “LAG-3” which is a cell surface molecule which plays a vital role in regulating T cells. LAG-3 was discovered by our Chief Scientific Officer and Chief Medical Officer Dr. Frederic Triebel, putting Immutep at the forefront of immunotherapy drugs for cancer and autoimmune diseases.
The companies objective is to harness and strengthen the power of the body’s own immune systems through therapeutic intervention for the benefit of patients’ health. This is how immunotherapy fights cancer and autoimmune disease.
LAG-3 IMMUNOTHERAPY PRODUCT CANDIDATES
Immutep has three clinical and one pre-clinical LAG-3 related product candidates under development, including two antibodies for modulating immune responses in cancer and autoimmunity, being advanced through pharmaceutical partnerships, with Novartis and GlaxoSmithKline.
Their lead product candidate is eftilagimod alpha (LAG-3Ig or IMP321), a first-in-class antigen presenting cell (APC) activator currently being investigated in clinical trials as a treatment (in combination with chemotherapy or immune therapy) for various cancer indications.
- Eftilagimod alpha (IMP321) – immunotherapy for cancer
- IMP761 – preclinical immunotherapy for autoimmune disease
- LAG525 or leramilimab (IMP701) – immunotherapy for solid tumors, blood cancer and breast cancer (partnered with Novartis)
- GSK‘781 (IMP731) – immunotherapy in autoimmune diseases (partnered with GSK)
Immutep is listed on the Australian Stock Exchange (IMM) and on the NASDAQ Global Market (IMMP) in the U.S. (ADR’s).